COMPARISON OF SINGLE VERSUS COMBINATION DRUG THERAPY IN EXTENSIVELY DRUG RESISTANT SALMONELLA TYPHI IN TERMS OF TIME TO DEFERVESCENCE

Starting soon · Not applicable

Conditions studied: Typhoid Fever

In brief

This randomized controlled trial will compare the effectiveness of single-drug therapy (meropenem) versus combination therapy (meropenem plus azithromycin) in children aged 2-16 years diagnosed with extensively drug-resistant (XDR) typhoid fever at the Children's Hospital, Lahore. A total of 94 patients will be enrolled and randomly assigned to either treatment group. The primary outcome is time to defervescence, defined as sustained resolution of fever for more than 48 hours. Secondary outcomes include duration of hospital stay and complication rates. The study aims to provide evidence to guide optimal management of XDR typhoid in pediatric populations."

Key facts

Study ID

NCT07641348

Run by

Iqra Asghar Ali

People needed

94

Starts

2026-07-01

Expected to finish

2027-02-01

Last updated by the study team

2026-06-11

Who can join

Age: 2 and older, up to 16. Sex: any. Healthy volunteers: not accepted.

You may not qualify if…

• Age <2 years or >16 years
• Known allergy or contraindication to meropenem or azithromycin
• Presence of severe comorbidities (e.g., congenital heart disease, chronic renal failure, immunodeficiency)
• Patients already receiving carbapenem or azithromycin therapy prior to enrollment

Where it is running

• University of Child Health Scienes Lahore — Lahore, Punjab Province, Pakistan

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.